版权说明 操作指南
首页 > 成果 > 详情

TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy

认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Zhao, Liqin;Qu, Xiaofei;Wu, Zhenhua;Li, Yuehua;Zhang, Xiaowei*;...
通讯作者:
Zhang, Xiaowei;Guo, WeiJian
作者机构:
[Zhao, Liqin; Zhang, Xiaowei; Guo, WeiJian; Wu, Zhenhua] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China.
[Qu, Xiaofei; Zhao, Liqin; Zhang, Xiaowei; Guo, WeiJian; Wu, Zhenhua] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.
[Qu, Xiaofei] Fudan Univ, Canc Inst, Shanghai Canc Ctr, Shanghai, Peoples R China.
[Li, Yuehua] Univ South China, Dept Med Oncol, Affiliated Hosp 1, Hengyang, Hunan, Peoples R China.
通讯机构:
[Zhang, XW; Guo, WJ] F
Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China.
Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.
语种:
英文
关键词:
TP53;immunotherapy;non-small cell lung cancer;somatic mutation;tumor mutation burden
期刊:
AGING-US
ISSN:
1945-4589
年:
2020
卷:
12
期:
14
页码:
14556-14568
基金类别:
This work was financially supported by the Natural Science Foundation of China (Grant No. 81871948).
机构署名:
本校为其他机构
院系归属:
医学院
摘要:
In this study, we investigated the association between TP53 somatic mutations and immunotherapeutic outcomes in non-small cell lung cancer (NSCLC) patients. Kaplan-Meier survival curve analysis of the MSK-IMPACT cohort of 350 NSCLC patients shows that overall survival (OS) is significantly lower for patients with truncating TP53 mutations than those with wild-type TP53 (OS: 9 months vs. 14 months; P=0.019). Multivariate analysis shows that truncating TP53 mutations are an independent predictor of immunotherapeutic outcomes. Moreover, among NSCLC patients with lower tumor mutation burden (TMB),...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com